Publication | Closed Access

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)

Hematological MalignancyLymphoid NeoplasiaChronic Lymphocytic LeukemiaMedicineImmunologyClinical TrialsImmune Checkpoint InhibitorPharmacotherapyImmunotherapyOncology